Merkel cell carcinoma (MCC) is a rare and aggressive skin tumor. The link between tumorigenesis and immunosuppression is well known and the increased prevalence of MCC in human immunodeficiency virus carriers and organ transplant recipients and in patients with hemato-oncological neoplasias is now well recognized over the past decade. In this respect, chronic lymphocytic leukemia (CLL) seems to be the most frequent neoplasia associated with the development of MCC. Very recently, a newly described virus, the Merkel cell polyomavirus, was found in 80% of MCC tumor samples and is in fact the first member of the polyomavirus family to be associated with human tumors. The virus appears to play a role in the pathogenesis of MCC and may constitute the missing link between immunosuppression and the development of MCC. This review summarizes the current knowledge relating to MCC and its pathogenesis, stressing the link with hematologic neoplasias in general and to CLL in particular. We describe the permissive immunologic environment, which enables the virus-containing tumor cells to survive and proliferate in disorders like CLL. More studies are still needed to confirm this appealing theory in a more convincing manner.
introduction
Merkel cell carcinoma (MCC) is a rare and aggressive skin tumor reported to occur with increasing prevalence in the past decade [1, 2] . One of the established features of MCC is its tendency to occur in association with other primary tumors, mostly skin and hematologic malignancies and in particular B lymphoproliferative disorders. In this respect, patients with chronic lymphocytic leukemia (CLL) seem to have the highest relative risk of developing this tumor [3] [4] [5] . Indeed, secondary malignancies are well recognized as one of the complications occurring in the course of CLL. It has been postulated that CLL itself as well as the different chemotherapeutic agents given for the disease permit the survival and proliferation of malignant cells, which would otherwise probably be eliminated by an intact and more effective immune system [5, 6] .
Recently, a major contribution to the improved understanding of the pathogenesis of MCC was made with the discovery of the association of polyomavirus with this rare tumor. This virus may indeed constitute the 'missing link' in relation to MCC and may explain in part the epidemiological association between B-cell malignancies and this tumor. This review focuses on the possible relation between MCC and lymphoproliferative diseases in general, with special emphasis on CLL as exemplified by the complex interplay of immune dysregulation and an infectious agent.
merkel cell carcinoma
Merkel cells were termed as such as they were first described by the German anatomist, Friedrich Merkel in 1875, as small round or oval basophilic cells located at the end of nerve axons and within the basal layer of the epidermis [7] . These cells have characteristic dense-core granules containing a variety of neuropeptides, plasma membrane spines and cytoskeletal filaments. The function of Merkel cells is still controversial today, but it is agreed that they are associated with the nerve terminals acting as mechanoreceptors, although the mechanism of transduction has as yet not been clearly defined. Other Merkel cells that have no contact with nerve terminals appear to have an endocrine function [3, 7, 8] .
MCC, also termed apudoma of the skin, trabecular cancer or small-cell neuroepithelial tumor of the skin, is an uncommon but aggressive cutaneous neuroendocrine tumor, first described by Toker in 1972 [9] . These were first reported as unusual skin tumors histopathologically, with anastomosing trabeculae and cell nests in the dermis and because of this the term 'trabecular carcinoma of the skin' was first used. Tumor cells are characterized by the presence of electron-dense neurosecretory granules, typically seen in cells associated with amine precursor uptake and the decarboxylation system, and since Merkel cells are the only type of cutaneous cells expressing such granules, the nomenclature of the tumor was changed to MCC [8] .
MCC is a rare tumor of the elderly with a median age of 70 years at diagnosis but its incidence has apparently increased threefold over the past 20 years and is estimated to be 4/ 1 000 000/year. It is twice as frequent in males as in females and most of the cases are of Caucasian origin [3, 7, 8] . MCC generally develops rapidly over a period of weeks to months, often spreading to local, regional and more distant sites. The mortality rate within 2 years of diagnosis is 28%, mostly because it is already metastatic at presentation. The 5-year survival rate for primary MCC is 75%, declining to 59% for patients with local metastases and 25% for those with distant metastases. Up to 50% of the patients will have disease recurrence within the first 2 years [3, 7] . Risk factors reported to be associated with the development of MCC include ultraviolet (UV) light exposure and immunosuppression. Most of the cases (81%) occur in the sun-exposed skin and the most common sites for tumor development are the head, neck and extremities, which also explains its frequent association with other skin cancers, such as squamous and basal cell carcinoma and Bowen's disease [8] .
Clinically, MCC usually presents as a firm red-violet cutaneous tumor nodule mostly dome-shaped while superficial ulceration, seen mostly in the later stages of disease, is uncommon [10] . The tumor spreads into the reticular dermis and subcutis usually sparing the papillary dermis, epidermis and adnexa. Essentially three histopathologic patterns are described, depending on the arrangement and appearance of the tumor cells-a trabecular form, an intermediate one and the small cell type. The mitotic index of the cells is usually high. Definitive diagnosis is established by positive staining for chromogranin, synaptophysin, neuron-specific enolase and the neural cell adhesion molecule (Figure 1 ), which represents both epithelial and neuroendocrine antigens present in normal Merkel cells. The expression of cytokeratin 20, found in the tumor cells in a dot-like paranuclear pattern and along the cytoskeleton, allows for unequivocal identification. The latter findings have been shown to be very useful in distinguishing MCC from metastatic small-cell carcinoma of the lung (cytokeratin 7+ and thyroid transcription factor 1+), small-cell melanoma (s100+) and non-Hodgkin's lymphoma (NHL) (leukocyte common antigen+) [11, 12] .
Clinical staging of the disease is based on tumor size (up to 2 cm or more) and the presence of local or distant metastases at presentation [13] . Basically, treatment options include surgery with or without adjuvant radiotherapy for localized disease and systemic chemotherapy for disseminated or recurrent disease [13] . It is not within the scope of this review to encompass the full details of available therapeutic options available but in short, the most effective treatment appears to rely on complete surgical excision (with a 3-cm margin of excision due to the high likelihood of local recurrence). Because of the high probability of lymphatic spread, a sentinel lymph node biopsy is usually carried out during surgery, and if micrometastases are identified, a wider lymph node dissection follows [13] . MCC is a radiosensitive disease and adjuvant radiotherapy delivered to original tumor site and the regional lymph nodes is also recommended. This addition has been shown to be effective in reducing recurrence and increasing the 5-year survival rate. There is no standard therapeutic regimen for metastatic MCC and the common chemotherapy regimens applied are based on those designed for small-cell bronchial carcinoma [13] , which includes anthracyclines, antimetabolites, bleomycin, cyclophosphamide, etoposide and platinum derivatives. This therapy is usually not curative but can be effective in reducing tumor bulk [13] .
Understanding of the pathogenesis and molecular events occurring in MCC is still limited. Although multiple chromosomal abnormalities including gains, losses and rearrangements have been detected [3] , the relationship of these genetic abnormalities to the pathogenesis of MCC remains unclear. In MCC, the most frequent chromosomes affected are 1, 11 and 13 and the pattern of chromosome gains and losses is similar to those encountered in small-cell carcinoma of the lung. Structural abnormalities involving chromosome 1p have been noted in up to 40% of examined cases and because deletion of chromosome 1 has also been associated with the development of malignant melanoma and neuroblastoma, it has been suggested that a tumor suppressor gene may be located in this region [7] . Despite extensive research on this topic, the understanding of molecular basis of MCC is still limited, and results of the analysis of the expression of target molecules such as bcl 2 or involvement of the Wnt pathway remain controversial [8] . A recent report demonstrated a very high expression (88%) of Mcl-1, which is part of the bcl 2 protein family and functions as an antiapoptotic protein in MCC. The same study also showed an increased expression (78%) of Bmi-1, a transcriptional repressor belonging to the polycomb-group family of proteins involved in the regulation of proliferation [14] . In several studies, expression of C-kit, a receptor tyrosine kinase, which is a potential activator of the mitogen-activated protein kinase pathway, was also found to be present in 15%-90% of MCC samples [14, 15] . Considering the limitations of the current therapies available for MCC and the relatively good results of targeted anticancer drugs and anti-angiogenesis agents, it seems likely that future clinical trials for MCC will be based on the use of multitargeted tyrosine kinase inhibitors.
the role of immune dysregulation
Many malignancies are considered to develop on immunosuppressive grounds. In this regard, the link with lymphoid neoplasias is especially important because they directly affect a major component of the immune system with associated influences on other non-lymphoid immune functions as well [16] .
Immunosuppression and dysregulation are well-established features of CLL and despite the fact that CLL is primarily a Blymphocyte-derived neoplasia, both cellular and humoral immunity are affected in this disease, including defects in both B-and T-lymphocytic functions, intercellular cross talk, natural killer cell activity, cytokine balance, complement levels and activity, as well as granulocytic and monocytic function [17, 18] . Especially prominent immune abberations in CLL include the presence of B-cell anergy [19] , hypogammaglobulinemia [20, 21] , decreased T-lymphocyte response to mitogens, abberant T-cell receptor and molecular expression on T cells [22] , increased numbers of regulatory T cells [23] and the inversion of the CD4+/CD8+ ratio, especially after treatment with purine analogues [17, 24] . A summary of the various immune dysfunctions encountered and described in CLL is presented in Table 1 .
Review of the available literature reveals a close link between MCC and immune dysfunction. Indeed, in the recently published 'AEIOU' acronym describing the clinical features of MCC, the letter 'A' = asymptomatic, E = expanding rapidly, 'I' = immunosuppression, O = older than 50 years and U = UV exopsed [10] . Chronically immune-suppressed individuals are 15 times more likely to develop MCC than age-matched controls [7, 25] and the disease occurs at a younger median age of 53 years. MCC also occurs more frequently after organ transplantation and after human immunodeficiency virus (HIV) infection and in patients with CLL. Sporadic association has also been reported in patients with multiple myeloma and in NHL [3] and even in patients with hairy cell leukemia years after therapy with purine analogues when patients are in clinical remission [26] . Based on a retrospective review of data during 1968-2000 conducted by Buell et al. [25] , 8% of all reported cases with de novo MCC have undergone solid organ transplant, mostly kidney (93%) but also heart (4%) and liver (4%) transplantations. MCC presented at a mean time of 82.5 (range 5-290) months after transplantation, usually with aggressive tumor spread with multiple sites of local or regional involvement (19% of patients) and a rapidly disseminating disease (51%) [25] . A recent retrospective study conducted by Heath et al. [10] on 195 patients with MCC showed that 7.8% of the patient cohort had some form of immunosuppression. CLL was particularly overrepresented (4.1%), with an ageadjusted incidence of 2.4% for 50-to 69-year-old patients and 6.5% for CLL patients >70 years old. This represents a 48-fold and 34-fold increased incidence, respectively, above that expected in the general population for these age groups [10] . In addition, Engels et al. [27] studied the incidence of MCC in 309 365 individuals with acquired immunodeficiency syndrome (AIDS), using linked AIDS and cancer registries, and reported that the incidence of MCC increased 11-fold for individuals with AIDS. There are in addition >10 reports of patients with spontaneous MCC regression and these seem to occur after incomplete tumor excision, biopsy or fine needle aspiration [28] [29] [30] [31] , while two cases of partial tumor regression after withdrawal of immunosuppressive therapy have also been reported [32, 33] . The latter data all seem to imply a crucial role of the immune system in the pathophysiology of MCC. Although the epidemiological link between immunesuppression and MCC is well established, it is still uncertain what the basic defects in the immune system are that permit the development, survival and growth of MCC tumors in immunecompromised patients. An RT-PCR-based analysis carried out on MCC tumor specimens has shown that the existence of a local cytokine imbalance might reflect a local permissive immune state [21] , but these findings still need further consolidation in order to really understand why MCC develops in these patients.
hematologic malignancies, particularly CLL and MCC
Although not yet fully understood, the link between MCC and hematologic malignancies, especially those of lymphoid derivation, is already well recognized [1, 3, 4, 6, 10, 34] . Possible explanations for this association include a predisposing genetic instability leading to an increased rate of mutation, exposure to oncogenic environmental factors and decreased immune surveillance associated with in the primary cancer, all permitting the development of second malignancies. These observations on MCC incidence may also reflect a certain degree of bias because of the closer follow-up carried out by minded physicians accompanied by more frequent clinic visits as well as an increased awareness by cancer patients after their diagnoses. Nevertheless, despite the latter assumptions, the consistency of data suggests that there is a true link between MCC and lymphoid neoplasias. The published reports imply a sort of a 'bidirectional' linkage between these diseases as there is an increased risk of MCC occurring in CLL patients while there is also an increased incidence of CLL evident in the MCC cohorts [3, 4, 10, 34] . Until now, more than 50 patients with concomitant CLL and MCC have been reported, mostly with CLL as the primary tumor. In 12 cases, MCC was the primary tumor, while in 2 cases, both were diagnosed simultaneously. A summary of these associations is given in Table 2 .
The most comprehensive study on the association of CLL with MCC was conducted by Howard et al. [3] on more than 2 million cancer patients' registries in the NCI Surveillance, Epidemiology, and End Results (SEER) program from 1986 to 2002 [3] . They identified an increased risk for developing NHL after MCC [standardized incidence ratio (SIR) = 2.56, 95% confidence interval (CI) 1.23-4.71, P = 0.007]; however, the risk for developing CLL following MCC was not seen as statistically significant (SIR = 2.72, 95% CI 0.55-7.94). Another recently published Finnish study by Koljonen et al. [4] found 2 patients among 172 with MCC (during the period of 1979-2006) who subsequently developed CLL. These findings reflect a significantly increased risk for CLL developing in patients with MCC (SIR = 17.9, 95% CI 2.2-64.6, P < 0.001) as opposed to [3] . Whether this apparent epidemiological assymetry between CLL and MCC is due to major differences in tumor prevalence rates (CLL is a common disease while MCC is a very rare one) or basically represents a manifestation of the permissive immunosuppression accompanying B-cell malignancies that allows for the development of secondary tumors is still a debatable issue. Another possible explanation for this observation lies in the fact that the median survival of patients with MCC is significantly shorter than CLL (median survival of 31 versus 120 months, respectively), which may imply that MCC patients do not live long enough to develop an indolent tumor while the reverse situation applies for CLL. In this respect, it is of interest to note that at least two case reports described not only the coexistence of both tumors in the same patient but even within the same skin lesion [48, 49] . Pathologically, both tumors belong to the 'small round and blue cell tumors' family, linking them both to the same differential diagnosis, sometimes with a confounding overlap [50, 51] .
Current available data and knowledge does not support a common origin for both these tumors, which arise from entirely different stem cells but there may perhaps be a common local transforming event, such as UV exposure or polyomavirus infection. A more plausible theory, however, would be of a first tumor causing an 'immunologic microrenvironment' facilitating the local development of a second tumor. All the above, in addition to the individual case reports, the small reported series and all the literature reviews recorded since the mid-1990s [12, 26, 31, 35-47, 48, 49] , strengthen the line of evidence, implying that immune dysfunction may well play a key role in the pathogenesis of MCC.
polyomavirus association with MCC
Murine polyomavirus was first discovered by Gross in 1953, while the first human polyomaviruses, BK virus (BKV) and JC virus (JCV), were coincidently isolated in 1971 by two independent groups. BKV was isolated from the urine of a renal transplant patient who had ureteral stenosis [52] and JCV was found in the brain tissue of a patient with Hodgkin lymphoma who developed progressive multifocal leukoencephalopathy [53] . Almost four decades later, DNA sequences, representing three new members of the human polyomavirus family, were discovered. The viral genomes cloned from these sequences have been designated KI polyomavirus (KIPyV), WU polyomavirus (WUPyV) and Merkel cell polyomavirus (MCPyV), respectively. KIPyV and WUPyV were identified from large-scale high-throughput screenings of respiratory secretions from patients with respiratory tract infections [54, 55] , while MCPyV was identified in MCCs using digital transcriptome subtraction, a methodology developed to identify foreign transcripts utilizing human high-throughput complementary DNA (cDNA) sequencing data [56] . In contrast to the four previously described human polyomaviruses, which belong to the simian virus 40 subgroup, MCPyV is phylogenetically related to murine polyomaviruses and is closely related to the African green monkey lymphotropic polyomavirus. Since the 1950s, polyomaviruses have been recognized as cancer viruses in animals, but MCPyV was basically the first polyomavirus suspected of causing human tumors. However, like in the case of other established tumor viruses, most individuals infected with MCPyV do not develop MCC and as yet, the additional steps required for the eventual development of cancer after infection with MCPyV are still unknown.
The human polyomaviruses, like other polyomaviruses, are composed of small, nonenveloped, icosahedral virions with a supercoiled double-stranded DNA genome (5200 base pairs) (Figure 2 ). The genomes are divided into three regions: first, the early coding region, which encodes for the large (Tag) and the small tumor antigen (tag); second, the late coding region, which encodes for the viral capsid proteins VP1, VP2 and VP3 and the nonstructural agnoprotein and third, the noncoding control region, which contains the viral promoters and the origins of replication. The MCPyV was first described in 2008 by Feng et al. who generated two cDNA libraries from four MCC tumors and then searched for rare viral sequences. They were able to define a previously unknown human polyomavirus, which they called Merkel cell polyomavirus (MCV or MCPyV) because of its close association with MCC. Sequences corresponding to MCPyV were found in 8 of the 10 MCC tumors compared with 5 of the 59 control tissues. Viral DNA in six of the eight MCPyV-positive MCC specimens showed a clonal integration pattern [56] . Since the discovery of the MCPyV, other researchers have obtained the same results, showing that 80% of MCCs have MCPyV integrated within the tumor, in a monoclonal pattern, indicating that the virus is present in a precursor cell before it becomes neoplastic. However, it should be noted that at least 20% of MCC are not infected with MCPyV, suggesting that MCC may have other nonviral causes as well [57, 58] .
MCC-related polyomaviruses have specific mutations of the large T antigen that render the virus noninfectious [59] . Such mutations were not detected in viral genomes from nonneoplastic cells, indicating that MCC cells undergo selection for Large T antigen mutations thus preventing autoactivation of integrated virus replication that would be detrimental to cell survival. Because these mutations render the virus 'replication incompetent', MCPyV is not regarded as a 'passenger virus', which infects MCC secondarily.
All in all, these results support the hypothesis that altered replication or integration of MCPyV may be involved in MCC tumorigenesis [59] . In this respect, it is worthwhile noting the observations of Shuda et al. who studied the MCPyV T antigen expression in normal lymphoid tissues and lymphoid tumors and in peripheral blood mononuclear (PBMN) cells obtained from healthy controls and HIV-positive patients without MCC in an attempt to assess the degree of MCPyV lymphotropism as described in other human polyomavirus infections. None of the samples obtained from healthy controls were positive for viral DNA; however, in PBMN collected from adult HIV/AIDS patients without MCC, 9.5% of cases were found to be positive for T antigen, suggesting that immunosuppression may indeed lead to reactivation of the latent virus [60] . They conclude that examination of the whole PBMN fraction is unlikely to reliably detect MCPyV in most infected individuals because of the dilution effect from the nonpermissive peripheral blood cells. On the other hand, they imply, like in the case of infections with other similar lymphotrophic viruses (e.g. Kaposi's sarcoma-associated herpesvirus) in which only a proportion of the peripheral blood mononuclear cells are positive in infected persons, that the lymphocyte pool may indeed serve as a tissue reservoir for MCPyV infection [60] .
In a recent study, Sihto et al. [61] reviewed 207 reports of MCC patients diagnosed in Finland during 1979-2004 and suggested that individuals with MCPyV-positive MCC tumors had a better prognosis than those without MCPyV infection (5-year survival: 45% versus 15% in univariant and multivariant analyses). An important observation gained from that study was a steady proportion of MCC cases that was positive for viral DNA during the two time periods studied, suggesting that MCPyV is probably not a new emerging threat, accounting for the increasing incidence of MCC [58] . It is obvious that in the near future a routine serological test needs to be developed in order to accurately measure exposure to MCPyV. Furthermore, we will also have to learn how to utilize the presence of the T antigen as a marker for MCC tumor cells and to determine whether this antigen can be exploited as a unique nonhuman target for specific anticancer therapy for MCC.
conclusions
The incidence of MCC, an aggressive skin tumor, has apparently been increasing over the past 20 years and it represents a new emerging complication in immunecompromised patients. Recognizing this entity is becoming an essential issue for hemato-oncologists today because an early diagnosis before the appearance of distant metastases is imperative due to the fact that this very aggressive tumor has a particularly poor overall survival when diagnosed late. The discovery of a new virus, the MCPyV, represents an important breakthrough in the attempts to understand the pathogenesis of MCC. The next steps, which are now under intensive research and need to be applied, relate to how to make an early diagnosis of MCC, through the detection of specific antigen markers and new serologic tests, and more importantly how to improve the therapeutic management of this aggressive tumor. Basic questions about the virus and its interaction with the host still remain unanswered and these include identification of the healthy carrier, determination of the mode of transmission of the virus in the normal population and the issue of its affinity to the cutaneous Merkel cells. Other questions relate to establishing whether there is anything unique about the Merkel cells that make them so susceptible to oncogenesis by this virus.
Development of new antiviral drugs, using small molecules that could perhaps interfere with the T antigen, and targeting MCPyV-tumor suppressor interactions are also now under development. Additional ongoing studies are in process and hold great promise for the ability to detect and combat these tumors in the not too distant future. 
